LY-3499446
- Generic Name
- LY-3499446
- Drug Type
- Small Molecule
- CAS Number
- 2409131-50-4
- Unique Ingredient Identifier
- QZJ1I2EN1V
A Study of LY3499446 in Participants With Advanced Solid Tumors With KRAS G12C Mutation
Phase 1
Terminated
- Conditions
- Advanced Solid TumorColorectal CancerNon-Small Cell Lung Cancer
- Interventions
- First Posted Date
- 2019-11-15
- Last Posted Date
- 2021-11-24
- Lead Sponsor
- Eli Lilly and Company
- Target Recruit Count
- 5
- Registration Number
- NCT04165031
- Locations
- 🇦🇺
Linear Clinical Research Ltd, Nedlands, Western Australia, Australia
🇺🇸Memorial Sloan Kettering Cancer Center, New York, New York, United States
🇺🇸Indiana Univ Melvin & Bren Simon Cancer Center, Indianapolis, Indiana, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.
© Copyright 2025. All Rights Reserved by MedPath